Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Share-based Compensation (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Share-based Compensation for 6 consecutive years, with $45858.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 120.28% to $45858.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $182896.0, a 74.22% decrease, with the full-year FY2024 number at $110723.0, down 87.41% from a year prior.
  • Share-based Compensation was $45858.0 for Q3 2025 at Ensysce Biosciences, down from $90638.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q1 2022 to a low of -$1.0 million in Q2 2022.
  • A 5-year average of $158256.6 and a median of $36373.0 in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 2971.54% in 2022, then soared 20964433.33% in 2023.
  • Ensysce Biosciences' Share-based Compensation stood at $16738.0 in 2021, then tumbled by 99.98% to $3.0 in 2022, then skyrocketed by 20964433.33% to $628936.0 in 2023, then crashed by 95.21% to $30149.0 in 2024, then soared by 52.1% to $45858.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Share-based Compensation are $45858.0 (Q3 2025), $90638.0 (Q2 2025), and $16251.0 (Q1 2025).